R. Rogers

DREAMM-6: Safety, Tolerability and Clinical Activity of Belantamab Mafodotin (Belamaf) in Combination with Bortezomib/Dexamethasone (BorDex) in Relapsed/Refractory Multiple Myeloma (RRMM)

A. Nooka, A. Khot, Deborah A. Smith, 2020 .

DREAMM-6: Safety and tolerability of belantamab mafodotin in combination with bortezomib/dexamethasone in relapsed/refractory multiple myeloma (RRMM).

A. Nooka, A. Khot, M. Mateos, 2020 .

Rapid initiation of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in acute and early HIV-1 infection: a DIAMOND subgroup analysis

Shubin Sheng, H. Hardy, K. Dunn, 2021, HIV research & clinical practice.

Oral Abstract: MM-459 Safety and Clinical Activity of Belantamab Mafodotin with Lenalidomide Plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): DREAMM-6 Arm-A Interim Analysis

J. Opalinska, M. Gironella, N. Patel, 2022, Clinical Lymphoma Myeloma and Leukemia.

Real-World Analysis of Weight Gain and Body Mass Index Increase Among Patients with HIV-1 Using Antiretroviral Regimen Containing Tenofovir Alafenamide, Tenofovir Disoproxil Fumarate, or Neither in the United States

P. Lefebvre, M. Lafeuille, C. Rossi, 2022, Journal of health economics and outcomes research.